National Cancer Institute   US National Institutes of Health | www.cancer.gov
US National Institutes of Health www.cancer.gov
BCSC
Breast Cancer Surveillance Consortium: Working together to advance breast cancer research
 
Home   |   Data   |   Statistics   |   Tools   |   Collaborations   |   Work with Us   |   Publications   |   About   |   Links

Performance Measures for 1,838,372 Screening Mammography Examinations1 from 2004 to 2008 by Age -- based on BCSC data through 2009

You are viewing the 2009 collection of this data. Data from other times are also available:
  Sensitivity2 Specificity3 Recall4 PPV15 PPV26 PPV37
Total 84.4% 90.8% 9.6% 4.3% 25.0% 29.0%
Age 18-39 76.5% 83.8% 16.3% 1.4% 8.2% 9.4%
Age 40-44 73.4% 87.7% 12.5% 1.6% 11.2% 13.0%
Age 45-49 82.5% 88.5% 11.8% 2.5% 16.7% 19.2%
Age 50-54 82.6% 90.4% 10.0% 3.6% 20.3% 24.0%
Age 55-59 85.7% 91.7% 8.6% 4.6% 26.4% 30.1%
Age 60-64 84.7% 92.2% 8.2% 5.9% 30.7% 35.9%
Age 65-69 86.3% 92.7% 7.8% 6.8% 33.7% 39.2%
Age 70-74 86.3% 93.3% 7.3% 8.0% 37.7% 43.0%
Age 75-79 88.4% 93.5% 7.1% 8.9% 41.3% 48.1%
Age 80+ 88.5% 93.8% 6.9% 10.9% 46.5% 55.0%

1  Screening mammography examinations: Mammography examinations indicated by the radiologist to be for screening with bilateral routine views done and no other mammogram within the last 9 months among women without breast implants or a prior mastectomy or a prior breast cancer diagnosis.

2  Sensitivity = The percentage of cancers§ that had a positive initial interpretation&.

3  Specificity = The percentage of non-cancers~ that had a negative initial interpretation#.

4  Recall = The percentage of examinations with a positive initial interpretation&.

5  PPV1 = The percentage of examinations with a positive initial interpretation& that result in a tissue diagnosis of cancer§.

6  PPV2 = The percentage of examinations with a positive final interpretation^ that result in a tissue diagnosis of cancer§.

7  PPV3 = The percentage of examinations with a positive final interpretation^, where it is known that a biopsy was performed as a result of the positive interpretation, that result in a tissue diagnosis of cancer within one year.

§  Cancers = Examinations with a tissue diagnosis of ductal carcinoma insitu or invasive cancer within one year and before the next screening mammography examination.

~  Non-cancers = Examinations without a tissue diagnosis of cancer within one year or before the next screening examination, whichever occurs earlier.

&  Positive initial interpretation = BI-RADS category 0, 4, or 5 (Note: category 3 with a recommendation for immediate follow-up was recoded as category 0).

#  Negative initial interpretation = BI-RADS category 1, 2, or 3 with no recommendation for immediate follow-up.

^  Positive final interpretation = BI-RADS category 4 or 5 (Note: categories 0 and 3 with a recommendation for biopsy were recoded as category 4).

Table numbers last updated September 23, 2013. The following source must be cited when reproducing this table: NCI-funded Breast Cancer Surveillance Consortium (HHSN261201100031C). Downloaded from the Breast Cancer Surveillance Consortium Web site - http://breastscreening.cancer.gov/.

[Return to Screening Performance]


National Cancer Institute Department of Health and Human Services National Institutes of Health USA.gov: The US government's official web portal Maintained by the Applied Research Program,
Division of Cancer Control and Population Sciences